Back

Efficacy and safety of baxdrostat in resistant and uncontrolled hypertension: a systematic review and meta-analysis of randomised controlled trials

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Aldosterone and hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Ms Juliana Ferraz De Sousa

(Brazil)

5 More presentations in this session

Presentation thumbnail
Impact of hyperaldosteronism in adults with hypertension: effects on long term risk of cardiovascular disease and all cause death
Mr A. Angelico-Goncalves (Vila Nova de Gaia, PT)
Abstract Slides
Presentation thumbnail
Opportunistic aldosterone testing during hypokalemia as an alternative confirmatory test for primary aldosteronism
Miss K. L (Singapore, SG)
Abstract Slides
Presentation thumbnail
Metabolic and inflammatory phenotypic divergence between primary aldosteronism and essential hypertension: a propensity score-matched cohort study
Professor T. Liu (Tianjin, CN)
Abstract Slides
Presentation thumbnail
Eplerenone vs irbesartan as first line therapy in obese hypertensive patients: results of the HEBRO randomized controlled trial
Doctor P. Iliakis (Athens, GR)
Abstract Slides
Presentation thumbnail
Baxdrostat for treatment of uncontrolled and resistant hypertension: a meta-analysis and systematic review
Doctor A. Bortolotto (Sao Paulo, BR)
Abstract Slides

Access the full session

Session thumbnail
Aldosterone and hypertension

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107
28 August 2022
thumbnail
Congress Presentation
Assessing the efficacy of renal denervation in patients with resistant arterial hypertension: a systematic review and meta-analysis
1 September 2024
thumbnail
Congress Presentation
Efficacy and safety of bisoprolol compared to other selective beta-1 blockers in the treatment of hypertension: a systematic review and meta-analysis of randomized parallel clinical trials
27 August 2021
thumbnail
Congress Presentation
Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources